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INTRODUCTION 
 
Labour induction is an obstetrical intervention designed to 
artificially initiate the process of cervical effacement, dilatation, uterine 
contractions and eventually delivery of the baby(1). The indications are 
postdated pregnancy, gestational diabetes, hypertensive disorders, fetal 
growth restriction and pre labour rupture of membranes. Sometimes it is 
essential to induce labour when the risk to the mother and / or fetus with 
pregnancy continuation outweighs the risk that are involved with 
intervention. Prolong labour, increased  instrumental delivery and 
increased cesarean section are more associated with Induction of labour 
with an unfavorable cervix compared to spontaneous onset of labour or 
induction of labour with a favorable cervix(2,3).  
The success of labour is decided by the improvement in the bishop 
score. Therefore, it is necessary to use optimal techniques for cervical 
ripening and safe confinement. 
There are many methods for labour induction which includes, 
prostaglandins, mechanical methods, membrane sweeping, oxytocin, 
antiprogesterone etc. 
3 
Uterine contractions are caused by the endogenous PGs. Some 
prostaglandins can be less shelf life and are not cost effective. One of the 
common methods to improve the bishop scoring and labour induction 
ever since 1968: PGE2 gel. Widespread use of this drug is limited 
because of its high cost, adverse effects and thermal instability leading to 
difficult storage(4,5,6). 
Because of the high costs and limited administration route of 
dinoprostone in recent years attention has turned world-wide towards  
another prostaglandin, "misoprostol", in the initiation of human labor at 
term. This medication, initially designed for the treatment of upper 
gastrointestinal ulcers has been shown to be an successful agent for 
induction of labour, when administered vaginally(7,8).There are more trials 
on use of this drug compared to any other drug in obstetrics and 
gynaecology. Finally after federal drug agency (FDA) approval in USA 
and the drug is used widely. 
 
Misoprostol is 15deoxy16hydroxy16CH3PGE1(PGE1) was the 
first synthetic analogue made available for the treatment of peptic ulcer(9). 
Impressed by its stimulant action on the uterus Sanchos Ramos in 1993 
used it for obstetrical indication. They act on the myometrium and causes 
contraction of smooth muscle fibres and cervical ripening (10). The peak 
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plasma concentration occurs at 30 minutes and then declines rapidly after 
oral administration (11) . It is stable at room temperature and does not 
require refrigeration(12). There is no evidence that dinoprostone gel is 
superior to oral misoprostol and it has lower rate of uterine 
hyperstimulation because the absorption of PGE1 is many tie s lesser 
when compared to PGE2. Oral PGE1 is particularly attractive because of 
easy and non invasive usage, particularly on an op basis(13). 
 
Rationale For Studying Misoprostol Administration In The Oral Form In 
The Induction Of Labour: 
 
Unlike vaginal preparations, oral labour induction agents reduces 
the number of pelvic examinations and thus reduces the incidence of 
chorioamnionitis by preventing repeated inoculation of cervix with lower 
vaginal organisms. 
 
Finally, as misoprostol was developed for oral administration, 
vaginal absorption has not been well studied. 
 
It is possible that oral misoprostol to induce labour might have a 
more smooth and predictable dose response curve than the vaginal 
misoprostol. We wished to evaluate whether or not misoprostol when 
administered orally, (the route for which it was marketed for its 
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gastrointestinal indications), would also be an effective and safe agent 
when compared to standard care in labour induction at term. 
 
Al1 prostaglandins administered orally for labour induction in 
previous reports had an unacceptable gastrointestinal side effect profile. 
 
Randomised control trial have investigated the role of  PGE1 in 
initiation of labour at term by improving the bishop scoring. The risk of 
caesarean section is reduced with oral misoprostol than convention 
dinoprostone gel. The advantages of oral misoprostol is that it is 
inexpensive, easy to store and easy to administer. 
The objective of this study is to determine whether oral 
misoprostol can safely and effectively replace dinoprostone gel for 
cervical ripening in women at term with an unfavourable cervix and 
intact uterus. 
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AIM 
 
A comparative study of safety and efficacy of oral misoprostol (25 
microgram) with dinoprostone gel (0.5mg) for cervical ripening and 
induction of labour. 
 
 
OBJECTIVES 
PRIMARY OBJECTIVE: 
To compare safety and efficacy of oral misoprostol (25 microgram) 
with intracervical dinoprostone gel (0.5 mg) for cervical ripening 
and induction of labour 
 
SECONDARY OBJECTIVE: 
 
1. To compare change in bishop score 
2. To compare mode of delivery 
3. To compare the need for augmentation of labour in active phase 
4. To compare patient satisfaction 
5. To compare side effects and neonatal outcome 
 
8 
 
 
 
 
 
 
 
 
 
 
Review Of Literature 
 
9 
REVIEW OF LITERATURE 
Labour induction is the process of initiating and augmentating the 
delivery of the fetus and placenta. 
 
HISTORIC PERSPECTIVES: 
 
The ability to induce has been of interest to many societies, from 
primitive to the ancient to the modern. There are two basic methods for 
labour induction, mechanical and chemical. There are various regimens 
that have been developed during the course of time in both of these areas. 
Information regarding primitive obstetrics is minimal. The depicters of 
primitive life, which have been archaeologically discovered, either in 
cave paintings or artefacts, were left by men. The birthing room, however 
was often closed to men and therefore was a mystery to them. Some 
concept of primitive medium can however be gleaned from observations 
of Native American practices.  
 
        Chemical methods of labour induction used by Native Americans 
were varied. Rattlesnake’s rattles were powered and administered in 
potion. Another potion was derived from bear claw scrapings. Additional 
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therapies included teas from the blossoms of Indian corn and berries of 
ground cedar bushes (14) 
 
        Dr. John Williams, a physician to the Green Bay Indian Agency, 
described the practice of a medicine man keeping before a parturient with 
a gourd in one hand that he constantly rattled and a pipe in his mouth 
from which he would blow smoke against her genitalia. It is not known 
whether this was a method to induce or to augment labour (14). 
 
    An observation of the parite tribe described the practice of having the 
pregnant women slowly decrease her consumption of food as she 
approached term. Physician in Greece, Rome and other contemporary 
societies wrote about labour induction. Hippocrates recommended two 
methods. One was nipple stimulation which would lead to uterine 
contractions and initiation of labour.  
 
       Soranus of Ephesus (AD 130) described the need for labour 
induction in patients with a small pelvis. The procedures that he 
recommended included emptying of a full bladder. Substances like water, 
oil, honey are mixed and given to empty the bowel; egg whites into the 
vagina to soften and relax the cervix. 
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        The Arab physician Abel Casis added to digital dilation a number of 
instruments that were used for labour induction and labour augmentation 
(15).  
        In the 16th century the French obstetrician Ambrois Pare derived 
another instrument for mechanically dilating a women’s cervix (16). The 
major achievement in labour induction was a convention in London in 
1756 that addressed for the first time the issue of labour induction in 
patients who had deformed pelvis. It was done by rupturing the 
membranes. This was adopted by Dr. Thomas Denman. 
 
        James in 1776 suggested that premature labour can be induced by 
venesection (17). Dewees, in the early 19th century believed that resistance 
of circular muscular fibres in uterus could be overcome by bleeding. In 
1810 Professor James Hamilton suggested manual stripping of 
membranes from lower uterine segment and then high rupture of 
membranes. This method gained popularity. In 1846, Dr. Kiwisch 
proposed using a stream of tepid water into the vagina, with labour 
commencing from 5-6 days. It was abandoned because of severe maternal 
mortality rates due to uterine rupture. In 1855, sponge tent developed. In 
1891, Pinard published 100 cases of premature induction of labour.  
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      In the late 19th century and early 20th century cervical dilatation 
continued to be much in vogue. In 1894 Lee developed a balloon that can 
be called a colpeurytner. The method of mechanical dilatation of cervix 
using bags or balloons reached its apogee with the Voorhees meteruynter. 
This was a rubber covered canvas bag that was deflated, inserted into the 
cervix and inflated with water.  
 
In the early 20th century ergot, quinine and pituitary extract became 
the primary medications for the induction of labour. In 1909 William 
Blair Bell started using pituitary extract, which he called infundibulin to 
initiate and augment labour. In 1928 Abel and Vincent identified the 
posterior pituitary hormones, oxytocin and vasopressin. In 1949, the first 
modern inducing agent, oxytocin was developed by Vigneaud. In 1953 he 
had synthesized oxytocin and showed that it was identical to natural 
oxytocin. 
 
In 1969, chemists were able to synthesise prostaglandins and stated 
the era of the use of prostaglandins in labour induction (18,19) . Karim first 
reported success with intravenous infusion of prostaglandin F, both this 
compound and prostaglandin El have been used widely for this purpose. 
Due to the unique effect of prostaglandins on the uterine cervix, they 
represent an excellent option for women who, on account of their 
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unfavourable cervix, are poor candidates for induction using oxytocin. 
Furthermore, because prostaglandins are effective when administered 
either locally or systemically, local administration has the advantage of 
requiring much lower doses of prostaglandin and avoids the problem of 
untoward side effects provoked by intravenous prostaglandin 
administration. The recent stable PGE2 preparation available in the 
market ,mainly vaginal pills and gel has boosted the clinical use of 
prostaglandins both for making the cervix favourable and for inducing 
labour. 
 
 
HISTORY OF PROSTAGLANDINS: 
In 1930, Kurzrock and Lieb, demonstrated the uterotonic effects of 
fresh human semen in vitro(20). Substances capable of provoking 
contraction of smooth muscle fibres were found in seminal fluid, by 
Goldblatt in 1933 and Von Euler 1934(21)."' Von Euler named these 
substances 'prostaglandins." Bergstrom and Sjovall isolated the first 
prostaglandin (PGFalpha) in 1957"and in 1964; the biosynthesis of 
several uterotonic prostaglandins was achieved. In 1969, Embrey 
suggested that equipotent doses of PGE2 were equally useful for elective 
induction of labour(22). Prostaglandins are known to play an important role 
in the physiology of human labour and it is likely that a late step in the 
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complicated series of events preceding the process of labor initiation is by  
endogenous local release of these substances. Most of the early clinical 
research was conducted with PGF2alpha, because it was thought to have 
more uterotonic activity and because of the initial "shelf instability" of 
PGE2. since the early 1970's, a significant number of trials for PG’s for 
labour induction have been conducted, studying issues of efficacy, 
different modes and  administration routes.  
 
From beginning there were various trials comparing  intravenous 
PG’s and IV syntocinon. Discovery of other different PG’s administration 
routes, the various trials have been made comparing  placebo, intravenous 
and buccal oxytocin and also PG’s in different routes and doses . The 
prostaglanding used for cervical softening has been studied 
comprehensively in various prostaglandin types, doses, and routes of 
administration (48). Meta-analyses have shown that prostaglandins are 
superior to placebo and oxytocin alone in ripening the cervix (49). 
 
Misoprostol (synthetic analogue of PGE1) has been the subject of 
numerous recent articles describing its use as a cervical ripening agent. 
Doses of 25 to 50 microgm administered vaginally or orally have been 
implemented in various trials to be successful in improving the bishop 
score.(50) 
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CERVICAL RIPENING AND INDUCTION OF LABOUR: 
Cervical ripening whether physiological or pharmacological is the 
conversion of rigid cervical sphincter associated with maintenance of 
pregnancy to a compliant and readily dilated structure. Cervical ripening 
occurs due to change in the cervical connective tissue. The major cellular 
component of the cervix is collagen and glycosaminoglycans (GAG) 
along with small amount of elastin. The commonest GAG in the cervix is 
chondroitin and dermatan sulphate. Obrink et al showed that the lower 
affinity of hyaluronic acid to bind with GAG molecule will destabilise the 
collagen. Alteration in the ratio between proteoglycan and GAG 
concentration can therefore alter the collagen affinity and accelerate 
collagen breakdown. Danforth et all 1960 (23) showed that the 
connective tissue of term cervix has less stable collagen fibrils with 
increase in intercellular matrix when compared to early gestation and non 
gravid state. There appears to be selective hyaluronic acid increment and 
selective decline in chondroitin sulphate (Von Maillot et al 1979 (24)) 
compared to non gravid cervix. 
 
Cervix score also known as Bishop score, is a method used to 
assess the cervix in pre labour to predict whether labour induction will be 
required(25).Bishop (4) developed a method for predicting the cervical 
favourability in multiparous patients with planned elective induction of 
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labor in which 0 to 3 points are given for each factor in the scoring 
system. When the cervix score was 9 and above, the probability of 
vaginal delivery was statistically insignificant between induced labour 
and spontaneous labour. 
The cervix score comprises of the following five components 
on vaginal examination: 
• Cervical dilation(closed to full dilatation) 
• Cervical effacement(uneffaced to well effaced) 
• Cervical consistency(firm to soft) 
• Cervical position(post to ant) 
• Fetal station(-3 to +3) 
 
Cervical scoring system categorises the antenatal mothers who would 
be the prime candidates to have a vaginal delivery. Bishop score and 
labour duration were not directly proportional; the bishop scoring of more 
than eight defines the antenatal mothers who are most likely to have 
vaginal delivery. Cervical ripening methods should be used before other 
methods with cervical scoring system of less than or equal to 5. 
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MISOPROSTOL: 
A synthetic analogue which is not recommended by Federal Drug 
Administration for labour initiation and ripening of cervix but American 
college of obstetrics & gynecology recommends misoprostol and it is on 
WHO essential drug list for induction of labour(26). Misoprostol is 
efficient smooth muscle stimulant. Many trials indicate its efficiency in 
oral administration (27). PGE1 is quickly absorbed when given orally. It is 
not recommended for intravenous use. Other routes of administration are 
sublingual (5), rectal (6), and vaginal. The major advantage of PGE1 is the 
ease of storage, transportation and good shelflife (28). Because of its oral 
route of administration there is increased patient satisfaction. 
 
A number of controlled trials which are published have shown that 
misoprostol, administered either vaginally or orally, is effective in 
improving bishop scoring and initiation of labour [53].  
 
In 1996, a double blind trial by Ngai et al in Hong Kong compared 
a single 200 microgm oral misoprostol dose versus placebo for softening 
of cervix, in PROM at term. Twelve hrs later if the participants were not 
in progressive labour, an intravenous oxytocin induction protocol was 
begun. Thirty-nine subjects received oral misoprostol, with 41 receiving 
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placebo. The Bishop score was significantly improved with misoprostol 
(P<O.O5). Thirty-four women given misoprostol went into labour 
without oxytocin, compared to 20 of those given placebo (P<0.001) . 
Interval to onset of uterine activity and delivery were both shorter with 
misoprostol (P<0.01). There were three caesareans in each group. 
Neonatal outcomes and gastrointestinal tolerance were comparable. The 
author recommended that oral PGE1 is an efficient mode of induction in 
this group of people (31).  Results published by Ramoz and Shetty et al 
concluded saying the same (32). Case reports were published with regard to 
the risk of rupture uterus during labor induction with misoprostol.(33)  
Results published by Bique et al demonstrated the safety profile of 
misoprostol  when used even in grand multiparous women with no 
significant adverse maternal or neonatal outcome. 
 
Ghazala et al determined the safety and efficacy of stepwise oral 
misoprostol (initially 50 μg followed by 100 μg every four hours upto 
maximum four doses) with vaginal misoprostol (25 μg every four hours 
up to maximum four doses) for initiation of labor, they concluded that 
irrespective of mode of administration the improvement in the cervical 
score was similar between both groups. The risk of tachysystole and c 
section rate was less with oral misoprostol when compared to vaginal 
PGE1 (34). 
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Alfirevic Z et al showed that, the ongoing trials have failed to 
prove that oral PGE1 is re is no evidence that oral misoprostol is 
substandard to the vaginal PGE1. The systemic absorption of PGE1 is 
many times lesser when compared to vaginal PGE1  and hence proves 
that the risk of tachysystole is less with oral PGE1(35).  
 
Cheng SY et al showed that In order to avoid uterine 
hyperstimulation, current suggestions are in favor of oral misoprostol 
given in small, frequent doses, titrated according to uterine response (36). 
It has been proved by many researchers by doing many controlled 
trials on animals that there is no risk of fetal malformation, deformation 
or any kind of teratogenicity to the fetus (37,38) 
 
Randomised control trial by Windrim R et al showed that 
differences in the dose of administration (ranging from 50 mcg to 200 
mcg) or intervals between the subsequent doses or single dose did not 
have much side effects in the controlled subjects of the study (39). 
 
Abbassi’s study, showed that even with low total dose of oral 
misoprostol (150 μg), the failure rate was only 2.5% in induction of 
labour (40) .The failure rate remains high with vaginal misoprostol (12-
15%). In this study the induction delivery interval was 6.7±4.4 hours. 
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Nigamas study showed that Oral PGE1 has been effective in 
reducing the duration of active phase of labour with no significant 
difference in neonatal outcome. (41)   
 
Cochrane review of trials with oral misoprostol has shown a lower 
risk of caesarean section (35) In Nigam’s, Dallen’s and Dodd’s studies this 
rate was 22.7%, 18% and 8.3% respectively(42). 
 
Literature shows that Oral PGE1 may increase the chances of 
meconium stained of liquor (35). The incidence of meconium staining in 
Dodd (16.2%) and Khatri (12%)(43) study.  
 
Dodd et all compared 25 microgm misoprostol with dinoprostone 
gel and showed that the statistical significance between the two groups 
was not significant enough in the many variables compared: 46% of 
PGE1 had duration of labor more than 24 hrs when compared to 41.2% of 
PGE2 gel; caesarean section rates was higher with PGE2 (26.6%) when 
compared to PGE1 (22.7%); abnormal uterine contraction was noted in 
0.8% of oral misoprostol and 1.6% in dinoprostone. They concluded that 
oral misoprostol and intracervical PGE2 are equally efficacious (42) 
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Trials using low doses of oral misoprostol, show low rate of 
caesarean section due to fetal distress and other complications but there 
were also less vaginal deliveries in 24 hours (44). 
 
Shazia Syed et al showed that the efficacy of oral PGE1 as a mode 
of initiation of labor by assessing the ease of administration , duration of 
labour was found to be less than 24 hrs in 99%, whereas 27% of the study 
samples had c section in which 41% had fetal distress as the indication, 
40% had MSL. Majority of the babies had good apgar at delivery. 
Tachysystole was noted in 0.4% (45) 
 
Kundodyiwa TW et al study  compared oral PGE1 (25 microgram) 
with PGE2 gel and vaginal PGE1, doses administered frequently like 
every 2 hours showed that the c section and hyperstimulation was more 
with PGE2 and vaginal PGE1.(46). 
 
An initial meta analysis by Sanchez Ramos et al showed a 
significantly reduced caesarean delivery rate for patients induced with 
oral misoprostol (25 microgm) (54). Follow-up meta-analyses have shown 
that use of misoprostol has less induction delivery intervals and a greater 
percentage of antenatal mothers had vaginal delivery within twelve to 
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twenty four hours. No evidence of adverse perinatal or maternal effects 
has been noted by Sanchez-Ramos L, Kaunitz AM (55).  
 
The number of subjects studied affords a power of at least 90% to 
detect a difference in neonatal intensive care unit admission rates of at 
least four percentage points (from 14% to 18%). Sufficient power also 
was noted for the detection of at least a doubling in the rate of abnormal 
5-minute Apgar scores    (from 1.4% to 2.8%). 
 
Sanchez Ramos also showed that Compared to women who 
received dinoprostone, Foley catheter, or placebo, women who received 
50 microgm misoprostol were two times more prone to develop abnormal 
uterine action, whose occurrence was directly proportional to the dose of 
misoprostol administered. Despite the increased incidence of 
hyperstimulation in the misoprostol group the number of caesarean 
deliveries performed for fetal heart rate abnormalities was similar 
regardless of the induction method used. Among all the patients induced 
with oral misoprostol , 84% went into active phase of labor , only 29% 
required acceleration. A significantly higher proportion of patients who 
received misoprostol experienced vaginal delivery within 12 hours 
(37.6% versus 23.9%). Similarly, 68.1% of patients who received 
misoprostol delivered vaginally within a day (24 hours). Use of PGE1 for 
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initiation of labour by improving the cervical scoring is associated with 
significant reduction in induction delivery interval (5 hours)(56) .  
 
In seven randomized trials have compared oral versus vaginal 
administration of misoprostol for labour induction (38, 57, 58). The oral doses 
ranged from 50 microgm to 200 microgm every 4 to 6 hours. Vaginal 
misoprostol was administered in doses that ranged from 25 microgm to 
100 microgm every 3 to 4 hours. No difference was noted in people who 
had normal delivery with half a day to one day. Similarly, the induction 
delivery interval were not different. Proportion of patients who 
experienced increased uterine activity (tachysystole or hyperstimulation) 
was similar for both groups. No difference was noted for the prevalence 
of abnormal Apgar and rates of NICU admissions. The rate of caesarean 
delivery was significantly lower among women induced with oral 
misoprostol.  
 
Kwon et al, Bennett et al,19 and Wing et al reported less effective 
inductions, whereas Windrim et al found a 50 microgm oral dose to be 
equally as effective in inducing labour as a 50 microgm  vaginal dose(57,58) 
 
In 2000, Jose L.Bartha compared oral PGE1with cervical PGE2 
initiation of labour. 200 antenatal mothers were randomised to single 
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dose of oral PGE1 200 micro gm or   cervical PGE2 gel 0.5 mg fourth 
hourly (maximum 2 mg). The induction delivery interval, prelabor 
rupture of membranes were shorter in oral PGE1 group.(60)   
 
Because of the small number of studies that use oral misoprostol 
and the lack of uniformity in dosing, the most appropriate dose of  oral 
PGE1 for labour induction has not been determined. Currently, it seems 
that oral doses of 100 mcg administered every 3 to 4 hours seem to be 
safe and effective. Further studies are needed to determine whether higher 
doses can improve efficacy without increasing the rate of adverse 
maternal and perinatal outcomes. 
 
Two trials done comparing vaginal PGE1 with cervical 
PGE2(Prepidil) (38,61) People were randomised to receive 50 mcg with 
interval being 3 hours for 6 doses and second group received 25 mcg at 
frequency of every 3 hours for 8 doses. The studies compared the efficacy 
of single drug in different doses (25 and 50). Those who received 50 mcg 
had shorter induction delivery interval and no differences in overall 
caesarean or operative delivery rates, caesarean deliveries for fetal heart 
rate abnormalities, or neonatal intensive care admission rates. Although 
subjects who received 50 mcg of misoprostol experienced a greater 
incidence of tachysystole, no significant increases in adverse maternal or 
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perinatal outcomes were noted. Meconium-stained fluid was noted more 
frequently for patients who received 50 mcg of misoprostol. Given the 
reassuring perinatal findings noted previously, this latter finding is of 
questionable importance. Because these two separate studies by Wing et 
al (38,61) indirectly compared two doses of misoprostol—25 microg and 50 
microg—they were incorporated into the current analysis. In total, 906 
patients were compared: 479 received doses of 25 mcg and 427 received 
doses of 50 mcg. Patients who received the 25mcg dose had a lower 
incidence of tachysystole and hyperstimulation; however, they also had a 
longer interval to vaginal delivery, and a lower proportion of these 
patients delivered vaginally within 12 to 24 hours. No differences were 
noted in the caesarean delivery rate, caesareans performed for fetal heart 
rate abnormalities, operative delivery rates, or neonatal intensive care unit 
admissions. 
 
In 2001, Michigan state university, USA. French L. Conducted a 
Cochrane study on oral PGE2 in induction of labour. The author found 
that it was associated with more gastrointestinal side effect compared 
with other treatment.  
 
The five studies comparing low-dose oral misoprostol with vaginal 
dinoprostone had 2,281 participants. Oral misoprostol was associated 
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with lower incidence of caesarean delivery (20.6% compared with 
26.7%). The statistical significance was not strong between any of the 
other primary or secondary impressions. There was significant 
heterogeneity in the analysis for the outcome of need for syntocin 
acceleration (P:0.11), abnormal uterine action without FHR 
changes(I2_83%, P_.001), and all maternal adverse effects (I2_51%, 
P_.67).(62) 
 
Low-dose oral PGE1 was compared with vaginal PGE1  in only 
two trials(40,46) containing 426 participants. In this comparison, the only 
statistically significant difference was that women given oral PGE1 had 
less tachysystole (2% compared with 13%) than those in the vaginal 
misoprostol group. 
 
One study compared two different regimens of oral PGE1 tablets in 
antenatal mothers with a low Bishop score.(63) One group received 25 mcg 
of oral PGE1 3 hourly for maximum 6 doses until they were getting three 
contractions every 10 minutes (irrespective of cervical dilatation). 
Oxytocin was only commenced if contractions later became inadequate or 
if the woman had received all six doses (this occurred in 77%). The other 
group received two doses of oral misoprostol 25 micrograms every 3 
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hours followed by routine oxytocin. There were no significant differences 
in any of the outcome measures of interest. 
 
In a randomised double blinded control trial conducted by Dodd et 
al, he randomised  365 samples for oral PGE1 and another 376 for 
cervical PGE2 gel. The statistical significance of primary outcomes like 
induction delivery interval <24 hours(PGE1 46% vs PGE2 41%), c 
section (22% vs 26%), fetaldistress as indication for c section( 8.8% vs 
9.3%). Uterine hyperstimulation was seen in 0.8% of oral misoprostol 
and 1.6% of cervical gel. The statistical significance was not of much 
difference between the two groups with regard to adverse perinatal or 
maternal outcome.Women’s satisfaction with oral misoprostol was 
assessed formally in only one study,(42) and more 58.8% expressed their 
liking for oral agent. 
 
High doses of oral or vaginal misoprostol are clearly effective at 
achieving vaginal delivery, but previous reviews have raised concerns 
relating to uterine hyperstimulation and adverse fetal outcomes. Lowering 
the dose of oral misoprostol does not seem to have resulted in lower rates 
of vaginal delivery.(35) 
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A Cochrane review16 focusing oral misoprostol for induction of 
labour included  two studies that used oral 200 microg misoprostol dose. 
This dose was associated with more tachysystole, but without evidence of 
better effectiveness in comparison with low-dose vaginal misoprostol. 
Most of the studies have used an oral dose of 50 mcg. It seems that higher 
oral doses (100 microg or more) are more effective, with more successful 
vaginal delivery within 24 hours. However, stronger uterine contractions 
and shorter labours have to be carefully balanced  against more uterine 
hyperstimulation, adverse neonatal outcomes and possibility of uterine 
rupture. 
 
In a trial conducted in Bangkok 146 women were randomised and 
divided into two groups , one group receiving 50 mcg of oral PGE1 and 
another group 25 mcg of vaginal PGE1. The induction delivery interval, 
improvement in cervical scoring, need for augmentation, complications 
like hyperstimulation and tachysystole,mode of delivery, neonatal apgar 
and need for NICU admissions were assessed. The induction delivery 
interval was longer with oral PGE1 (16 hrs) the neonatal outcome was 
equal among both the groups as per the apger score and the NICU 
admissions. The conclusion of the study was though the higher dose was 
used for oral administration the lesser  vaginal dose was found to be more 
effective in improving the cervical scoring. (66) 
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Langenegger E.J. Odendaal H.J. Grove Det al randomised 200 
patients to receive 50 mcg of oral PGE1 every 4h and another 200 to 
receive 0.5 mg cervical gel every 6h. As the primary outcomes the safety 
and efficacy of the drug was assessed by comparing the CTG and the 
induction delivery interval between the two groups. They failed to 
demonstrate any statistical significance between the two groups as far as 
the induction delivery interval is concerned. The CTG to demonstrate the 
fetal heart rate abnormalities was taken after each mode of induction and 
compared. The outcome was the heart rate abnormalities was non 
reassuring among the samples who had PGE2 gel induction when 
compared to PGE1. The suspicious and pathological variants of the CTG 
was not statistical significance between the two groups. Perinatal 
outcome did not significantly differ. The conclusion was both PGE2 and 
PGE1 are as efficacious as far as induction is concerned but with lesser 
difference of abnormalities of CTG as shown by the PGE2 group.(67) 
 
Gherman RB et al in a randomised trial showed that Sixty patients 
were enrolled, with 29 randomized to the oral misoprostol arm and 31 to 
the prostaglandin E2 group. The data on 58 patients were eligible for 
analysis. Delivery occurred within 48 hours in 96.4% (27/28) of those 
administered oral misoprostol as compared to 76.7% (23/30) of those 
who received intravaginal prostaglandin E2 (P =.03). The mean time 
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intervals from the start of induction to delivery were similar between the 
two groups (1,496 +/- 120 vs. 1,723 +/- 230 minutes, P =.40). No 
statistically significant differences existed between the two groups with 
respect to intrapartum complications, tachysystole, uterine 
hyperstimulation or adverse neonatal outcomes(68). 
 
According to NICE guidelines Induction of labour, for all women 
irrespective of parity, membrane and cervical status, caesarean birth was 
less likely to occur with oral misoprostol (50-100 microgram) when 
compared with PGE2.Maternal and fetal outcomes were comparable 
between oral misoprostol and intracervical dinoprostone. Compared with 
vaginal misoprostol(25 microgram every 4 hours , maximum dose 150 
micrograms), primiparous women with unfavourable cervix given oral 
misoprostol (50 microgram every 4 hours, maximum dose 300 
micrograms)were  significantly less likely to achieve vaginal birth within 
24 hours. However maternal and analyses of outcomes of all women 
suggested that oral misoprostol (50-100 microgm) may be associated with 
a reduced risk of caesarean birth. There were no perinatal deaths. 
Additional RCTs identified found vaginal misoprostol 50micrgms to have 
a higher incidence of uterine hyperstimulation when compared with oral 
misoprostol 100 microgms. Titrated low dose oral misoprostol 25 
microgms was more effective in terms of achieveing vaginal birth within 
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24 hours and reduced the caesarean birth rate,in women with prelabour 
rupture of membranes.   
 
Bartha et al (69) in his study said that though the induction delivery 
interval was less with the oral PGE1 the risk of hyperstimulation could 
not be outweighed. 
 
ACOG Committee would like to emphasize that the following 
clinical practices appear to minimize the risk of uterine hyperstimulation 
and  rupture in patients undergoing cervical ripening or induction in the 
third trimester(59) 
 
1) If misoprostol is to be used for cervical ripening or labor induction 
in the third  trimester, one quarter of a 1OOmcg tablet (ie, 
approximately 25mcg) should be considered for the initial dose.  
2) Doses should not be administered more frequently than every 3-6 
hours.  
3) Oxytocin should not be administered less than 4 hours after the last 
misoprostol dose.  
4)  Misoprostol should not be used in patients with a previous cesarean 
delivery or prior major uterine surgery. 
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According to ACOG The use of higher doses of misoprostol (eg: 
50 microgm every 6 hours) to induce labour  may be appropriate in some 
situations, although there are reports that such doses increase the risk of 
complications, including uterine hyperstimulation and uterine rupture (59)b 
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MATERIALS AND METHODS 
The study was conducted in the department of obstetrics and 
gynecology, PSG Hospitals, Coimbatore from August 2012 to August 
2013. 
STUDY DESIGN: 
Prospective study 
STUDY POPULATION: 
Study group consisted of two groups. These groups constituted of 
pregnant women at term admitted to PSG hospitals for induction of 
labour for either medical or obstetrics reasons. 
SELECTION CRITERIA: 
1. singleton pregnancy 
2. vertex presentation 
3. bishop score<5 
4. completed 37 weeks 
5. need for induction 
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EXCLUSION CRITERIA: 
1. multiple gestation 
2. non vertex presentation 
3. preterm 
4. previous LSCS 
5. multiparity 
6. cephalopelvic disproportion 
Patients who needed induction were identified and selected for 
induction by random allocation table. After obtaining informed consent 
they were induced with PGE2 gel and oral misoprostol by whichever 
method they were selected. 
PATIENT PREPARATION: 
Consent for induction after explaining about the method of 
induction. Any patient coming under exclusion criteria were excluded. 
After informed consent has been obtained, the patients selected for the 
study were evaluated initially by Bishop’s score and admission test for 
fetal well being. Patients with Bishop’s score <5 and positive admission 
test were induced. 
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PGE2 GEL PLACEMENT: 
DINOPROSTONE PGE2 GEL: 
 
 
 
Under aseptic precaution prostaglandin gel 0.5 mg is instilled 
endocervically. 
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ORAL MISOPROSTOL 25MICROGMS 
¾ Analysing criteria: 
104 patients with an indication for induction received  25microgm 
misoprostol orally and repeated for a maximum of 3 doses every 6 hours 
as needed. 
 
107 patients with an indication for induction of labour received 
0.5mg dinoprostone gel intracervically and repeated for a maximum of 3 
doses every 6 hours as needed. 
 
The bishop score was evaluated after each dose of dinoprostone gel 
whereas in oral misoprostol it was evaluated only when the patient had 
good contractions, bleeding or draining per vaginum otherwise it was 
analysed only after 3 doses. 
 
The change in bishop score after induction was evaluated. If the 
score was moderately favourable it was augmented with vaginal 
misoprostol in both the groups. If the score was very favourable and in 
active phase of labour, it was accelerated with oxytocin or artificial 
rupture of membranes or both. Course of labour was monitored using a 
partogram and the following outcome were measured. 
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Outcome measure: 
1. change in bishop score 
2. time interval from induction to onset of adequate uterine 
contraction 
3. need for augmentation of labour 
4. mode of delivery 
5. side effects 
6. patient satisfaction and cost of induction 
7. neonatal outcome 
 
  Bishop’s system of cervical scoring was used to find the pre 
induction and post induction status of the cervix. A score of 5 and less 
than 5 was taken as criteria for induction and score more than 6 was 
found to be favourable after induction. 
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 BISHOP’S SCORE   
                
MODE OF DELIVERY: 
The mode of delivery in these patients were noted. Caesarean 
section rates of both groups were compared. 
DURATION: 
The  induction - delivery was analysed between these groups, to 
find out shorter duration of induction to delivery interval method out of 
these two methods. 
 
AUGMENTATION AND ACCELERATION: 
Need for further augmentation in both PGE2 gel and oral 
misoprostol groups were noted. In PGE2 gel group, if the bishop score is 
unfavourable then another dose was used, maximum 3 doses of gel were 
used at 6 hours interval. Still if the score was not very favourable it was 
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augmented with vaginal misoprostol 25microgram which was kept to a 
maximum of 3 doses four hours apart. Labour was accelerated with 
oxytocin and artificial rupture of membranes according to pervaginal 
findings. 
 
In oral misoprostol group, reassessment was done after 3 doses or 
if there was strong contraction,bleeding or draining per vaginum. If the 
bishop score was not very favourable it was augmented with vaginal 
misoprostol 25microgram which  was kept to a maximum of 3 doses four 
hours apart. Labour was accelerated with oxytocin and artificial rupture 
of membranes according to pervaginal findings.  
 
PERINATAL OUTCOME: 
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RESULTS 
During the study period, a sum of 211 patients were included.107 
were induced with PGE2 gel(0.5mg) and 104 patients with oral 
misoprostol (25mcg). The two groups were statistically similar with 
respect to age and gestational age.                                                
TABLE 1: AGE DISTRIBUTION OF PATIENTS 
AGE IN 
YEARS 
PGE2 GEL ORAL MISOPROSTOL 
No % No % 
18-20 6 5.6 3 2.9 
21-25 76 71.0 68 65.4 
26-30 25 23.4 31 29.8 
>30 0 0.0 2 1.9 
Total 107 100.0 104 100.0 
Mean ± SD 23.98 ± 2.49 24.65 ± 2.23 
Samples are age matched with p=0.041 
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TABLE 2:  GESTATIONAL AGE IN WEEKS 
GESTATIONAL 
AGE IN WEEKS 
PGE2 GEL 
ORAL 
MISOPROSTOL 
No % No % 
37-40 78 72.9 81 77.9 
40-42 29 27.1 23 22.1 
Total 107 100.0 104 100.0 
Mean ± SD 39.34 ± 0.94 39.25 ± 0.97 
Gestational age is both statistically similar with p=0.514 
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TABLE 3:  INDICATION FOR INDUCTION 
INDICATION FOR 
INDUCTION 
PGE2 GEL ORAL MISOPROSTOL 
No % No % 
Oligo 16 15.0 11 10.6 
Chronic SHT 0 0.0 1 1.0 
Term 44 41.1 60 57.7 
Post dated 28 26.2 21 20.2 
GDM 7 6.5 3 2.9 
Pre eclampsia 4 3.7 0 0.0 
IUGR 4 3.7 6 5.8 
NR, NST 2 1.9 2 1.9 
precious pregnancy 1 0.9 0 0.0 
severe PE, IUGR 1 0.9 0 0.0 
 
 
 
 
 
The most common indication is term patients who do not enter into 
spontaneous labour. The next common indication is post dated 
pregnancy. 
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TABLE 5- PRESCORE COMPARISON 
 
PRESCORE 
PGE2 GEL ORAL MISOPROSTOL 
No % No % 
0 3 2.8 4 3.8 
1 12 11.2 13 12.5 
2 32 29.9 32 30.8 
3 32 29.9 29 27.9 
4 27 25.2 26 25.0 
5 1 0.9 0 0.0 
Mean ± SD 2.66 ± 1.08 2.57 ± 1.11 
Inference Prescore does not differ in two groups with P=0.568 and therefore there is no statistical significance 
 
 
 
 
 
 
 
 
 
46 
TABLE 6- POSTSCORE COMPARISON 
 
POSTSCORE 
PGE2 GEL ORAL MISOPROSTOL 
No % No % 
0-3 4 4.8 11 13.4 
4-7 71 66.4 42 40.4 
8-10 24 22.4 53 51.0 
>10 0 0.0 4 3.8 
Mean ± SD 6.0 ± 2.08 7.60 ± 2.09 
Inference Post score differs in two groups with P=0.000 and therefore there is statistical significance 
 
Post bishop score of 0-3 is more in oral misoprostol group(13.4%). 
The improvement in bishop score with 0-3 was less with oral misoprostol 
and hence the rate of failed induction was high. But the overall 
improvement in bishop score was better with oral misoprostol. 
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TABLE 7:  COMPARATIVE EVALUATION OF INDUCTION 
SCORE 
BISHOP SCORE PGE2 GEL 
ORAL 
MISOPROSTOL 
P VALUE 
Pre Induction score 2.66 ± 1.08 2.57 ± 1.11 0.568 
Post Induction Score 6.00 ± 2.08 7.60 ± 2.09 0.000 
P value >0.001 <0.001  
 
The pre induction score was similar in both the groups with a mean 
of 2.66 ± 1.08 in PGE2 gel group and 2.57 ± 1.11 in oral misoprostol 
group. There was a significant change in bishop score in both groups but 
in oral misoprostol, the cervix once it became favorable it progressed 
very smoothly with significant difference of p<0.001. 
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TABLE 8:  NO OF DOSES 
NO OF 
DOSES 
PGE2 GEL ORAL MISOPROSTOL 
No % No % 
1 32 29.9 20 19.2 
2 44 41.1 32 30.8 
3 31 29.0 52 50.0 
Mean ± SD 1.99 ± 0.77 2.30 ± 0.78 
Inference 
Doses are not statistically similar in two groups with 
P=0.003 
 
 
50% of oral misoprostol group needed 3 doses and only 31% PGE2 
gel needed 3 doses.  
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TABLE 9- PRESCORE & NO OF DOSES- PGE2GEL 
 
PRESCORE 
1 DOSE 2 DOSE 3 DOSE 
No % No % No % 
0 1 33.3 0 0.0 2 66.7 
1 0 0.0 6 50.0 6 50.0 
2 14 43.8 9 28.1 9 28.1 
3 8 25.0 16 50.0 8 25.0 
4 9 33.3 12 44.4 6 22.2 
5 0 0.0 1 100.0 0 0.0 
Inference P=0.187, there is no statistical significance 
 
 
 
 
 
 
 
 
 
 
 
50 
 
TABLE 10- PRESCORE & NO OF DOSES- ORAL 
MISOPROSTOL 
 
 
PRESCORE 
1 DOSE 2 DOSE 3 DOSE 
No % No % No % 
0 0 0.0 0 0.0 4 100.0
1 1 7.7 3 23.1 9 69.2 
2 4 12.5 10 31.2 18 56.2 
3 5 17.2 9 31.0 15 51.7 
4 10 38.5 10 38.5 6 23.1 
5 0 0.0 0 0.0 0 0.0 
Inference P=0.003, there is statistical significance 
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 TABLE 11:  AUGMENTATION 
AUGMENTATION 
PGE2 GEL ORAL MISOPROSTOL
No % No % 
Nil 52 48.6 64 61.5 
Cytotec 55 51.4 29 27.9 
PGE2Gel 0 0.0 11 10.6 
Mean ± SD 1.99 ± 0.77 2.30 ± 0.78 
Inference 
Augmentations are statistically similar in two 
groups with P=0.774. Incase of cytotec and 
PGE2Gel, there is statistical significance with p 
values 0.000 and 0.000 
 
In both the groups, labour was augmented. The need for 
augmentation was more with PGE2 gel. In oral misoprostol group, 38% 
needed augmentation of which 11 patient had failed induction and they 
were induced with PGE2 gel. The need for cytotec augmentation was 
more with PGE2 gel. 61.5% did not require augmentation in misoprostol 
group while 48.6 did not require augmentation in PGE2 gel group.  
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TABLE 12 INDUCTION IF FAILED ORAL MISOPROSTOL: 
 
AUGMENTATION 
PGE2 GEL 
ORAL 
MISOPROSTOL 
No % No % 
PGE2Gel 
LSCS 0 0.0 10 90.9 
NVD 0 0.0 1 9.1 
 
TABLE 13:  ACCELERATION 
ACCELERATION 
PGE2 GEL ORAL MISOPROSTOL
No % No % 
Nil 7 6.5 37 35.6 
ARM 18 16.8 15 14.4 
Synto 22 20.6 15 14.4 
Synto + ARM 60 56.1 37 35.6 
Total 107 100.0 104 100.0 
Inference 
Acceleration is not statistically similar in two 
groups of patients with P=0.000 and therefore there 
is statistical significance 
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37 patients in oral misoprostol did not need acceleration and 93% 
of PGE2 gel needed acceleration and in that  60% needed both ARM and 
synto . 64% oral misoprostol needed acceleration and in that only 37% 
needed acceleration with both ARM and synto. 
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TABLE 14:  MODE OF DELIVERY 
MODE OF 
DELIVERY 
PGE2 GEL ORAL MISOPROSTOL 
No % No % 
LSCS 37 34.6 33 31.7 
NVD 70 65.4 71 68.3 
Total 107 100.0 104 100.0 
Inference 
Mode of delivery is statistically similar in two groups pf 
patients with P=0.289 
 
33 patient had lscs in oral misoprostol but it was not statistically 
significant. Out of 104 cases 68.% had normal vaginal delivery. 
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TABLE 15- PRESCORE AND MODE OF DELIVERY- PGE2GEL 
 
PRESCORE 
LSCS NVD 
No % No % 
0 1 33.3 2 66.7 
1 6 50.0 6 50.0 
2 14 43.8 18 56.2 
3 10 31.2 22 68.8 
4 6 22.2 21 77.8 
5 0 0.0 1 100.0 
Inference P=0.433, there is no statistical 
significance 
 
50% with score 1 had lscs and 77% with score 4 had vaginal 
delivery. 
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TABLE 16- PRESCORE AND MODE OF DELIVERY- ORAL 
MISOPROSTOL 
 
PRESCORE 
LSCS NVD 
No % No % 
0 1 25.0 3 75.0 
1 6 46.2 7 53.8 
2 13 40.6 19 59.4 
3 11 37.9 18 62.1 
4 2 7.7 24 92.3 
5 0 0.0 0 0.0 
Inference P=0.039, there is statistical 
significance 
 
46% with score 1 underwent lscs and 92% with score 4 had vaginal 
delivery 
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TABLE 17:  INDICATION FOR LSCS 
INDICATION 
FOR LSCS 
PGE2 GEL ORAL MISOPROSTOL 
No % No % 
Fetal distress 23 62.2 14 42.4 
Failed 
Induction 5 13.5 11 39.4 
Non 
progression of 
labour 
9 24.3 6 18.2 
Inference 
Indication of LSCS is statistically similar in two groups 
with p= 0.486 and therefore there is no statistical 
significance. In case of fetal distress, failed induction 
and non progression of labour, there is no statistical 
significance with the p values of 0.126, 0.098 and 0.579 
 
 
[ 
The most common indication for LSCS was fetal distress in both 
the groups. Failed induction was comparatively more with oral 
misoprostol but it was not statistically significant. 
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TABLE 18: INDUCTION DELIVERY INTERVAL 
INTERVAL 
(HRS) 
PGE2 GEL ORAL MISOPROSTOL 
No % No % 
<12 hours 15 14.0 21 20.2 
12-24 hours 48 44.9 41 39.4 
24-36 hours 28 26.2 22 21.2 
36-48 hours 14 13.1 11 10.6 
>48 hours 2 1.9 9 8.7 
Mean ± SD 23.57 ± 11.90 25.15 ± 13.95 
Inference  
Delivery interval (>48 hours) is statistically similar in two 
groups with p=0.141 and therefore there is no statistical 
significance. 
 
The mean duration of induction to delivery is more with oral 
misoprostol (25.15 ± 13.95) and mean duration in PGE2gel(23.57 ± 
11.90). But 21 of oral misoprostol had significantly shorter duration 
interval in comparison to 15 in PGE2 gel. In oral misoprostol 8.7% had 
interval more than 48 hours in contrast to 1.9% in PGE2 gel but it was not 
statistically significant. 
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TABLE 19: 
 
Interval (hrs) 
pge2 gel oral misoprostol 
No % No % 
>48 hours 
LSCS 2 100.0 6 66.7 
NVD 0 0.0 3 33.3 
 
 
In those with more than 48 hrs interval 66% had lscs and 33% had 
vaginal delivery 
 
TABLE 20:  COMPLICATIONS 
COMPLICATIONS 
PGE2 GEL 
ORAL 
MISOPROSTOL 
No % No % 
Normal  59 55.1 76 73.1 
Abnormal Fetal distress 43 40.2 25 24.0 
Fever 1 0.9 3 2.9 
Hyperstimulation 4 3.7 0 0.0 
Inference 
Incidence of complications are not 
statistically similar in two groups of 
patients studied with P=0.005 
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Incidence of complication is less in oral misoprostol (26.9%). 
Among them 25% had fetal distress and none had hyperstimulation. In 
contrast PGE2 gel 44.8% had complication and in them 43% had fetal 
distress and 4% had hyperstimulation. 
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TABLE 21:  APGAR SCORE 1 MINUTE 
APGAR 
SCORE AT 
1 MINUTE 
PGE2 GEL ORAL MISOPROSTOL 
No % No % 
1 -6 13 12.1 10 9.6 
7 -10 94 87.9 94 90.4 
Mean ± SD 7.47 ± 0.98 7.50 ± 1.09 
Inference 
Incidence of low Apgar score is statistically similar in 
two groups with P=0.871 
 
Statistically similar apgar score was obtained in both the groups. 
No NICU admission and neonatal death was noted. 
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Table 22:  Apgar score 5 minute 
APGAR 
SCORE AT 
5 MINUTE 
PGE2 GEL ORAL MISOPROSTOL 
No % No % 
1-6 6 5.6 2 1.9 
7-10 101 94.4 102 98.1 
Mean ± SD 8.55 ± 0.84 8.59 ± 0.87 
Inference Incidence of low Apgar score at 5 minutes is statistically similar in two groups with P=0.707 
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TABLE 23:  POST NATAL COMPLICATIONS 
POST NATAL 
COMPLICATIONS 
PGE2 GEL 
ORAL 
MISOPROSTOL 
No % No % 
Nil 103 96.3 100 96.2 
PPH 3 2.8 2 1.9 
Retained placenta 1 0.9 0 0.0 
Perineal tear 0 0.0 2 1.9 
Inference 
Incidence of post natal complications are 
statistically similar in two groups of patients 
studied with P=0.536 
 
 
1.9% had complete perineal tear and 1% had retained placenta in 
PGE2 gel but post natal complication was statistically insignificant in 
both groups 
 
 
 
64 
TABLE 24 –COST OF INDUCTION 
COST 
PGE2 GEL ORAL MISOPROSTOL 
No % No % 
<200 0 0.0 104 100.0 
200-500 76 71.0 0 0.0 
>500 31 29.0 0 0.0 
Mean ± SD 443.69 ± 176.07 9.2 ± 3.1 
Inference 
costs are not statistically similar in two groups with 
P=0.000 
 
 The mean cost of induction in oral misoprostol is Rs.9 and in 
PGE2 gel is Rs.450. This is 50 times more than the amount used for oral 
misoprostol. Hence oral misoprostol is better cost effective than PGE2 
gel 
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DISCUSSION 
Ian Donald defined induced labour is “the one in which pregnancy 
is terminated artificially anytime after the period of viability by a method 
which aims to secure delivery via naturalis.” Williams states that 
induction of labour implies stimulation of uterine contraction before 
spontaneous onset of labour with or without rupture membrane.  
INDICATIONS FOR INDUCTION (ACOG technical bulletin 
157,1991) 
1.  gestational hypertension 
2. PROM 
3. abruption placentae 
4. chorioamnionitis 
5. suspected  
• Absence of fetal well being 
• IUGR 
• Post term pregnancy 
• Isoimmunisation 
6. maternal medical problems 
7. fetal demise 
67 
CONTRAINDICATION FOR INDUCTION(ACOG bulletin 
157,1991) 
1) Major degree of cephalopelvic disproportion 
2) Placenta previa 
3) classical caesarean section 
4) Cord presentation 
5) Prior myomectomy or uterine unification surgery 
6) Active genital herpes infection 
7) Pregnancy following VVF repair 
8) Malpresentation 
9) Invasive cervical carcinoma 
RISKS OF INDUCTION: 
A. MATERNAL: 
1. Psychological upset 
2. Need for emergency caesarean delivery 
• Fetal distress 
• Failed induction 
3. Placental abruption 
4. Precipitate delivery 
5. Abnormal uterine action 
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6. Atony of uterus  
7. Water intoxication and electrolyte imbalance 
8. Infection 
9. Amniotic fluid embolism 
B. FETAL 
1. Iatrogenic prematurity 
2. Fetal hypoxia 
3. Neonatal jaundice in association with oxytocin 
FACTORS TO BE CONSIDERED WHEN ELECTING TO 
INDUCE ARE: 
1. Patients informed consent 
2. Estimation of fetal pulmonary maturity 
3. Estimation of gestational age 
4. Pelvic adequacy 
5. Readiness of cervix 
6. Bishop scoring system 
7. Stability of maternal condition 
8. Uterine integrity 
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METHODS OF INDUCTION IN RELATION TO STATE OF 
CERVIX: 
 CERVICAL 
STATE  
INDUCTION 
METHODS 
 
1. Unfavourable 
cervix(nulliparous 
score <5) 
Medical 1.myometrial 
stimulants 
 
2.cervcial 
modifying drugs
a. Prostaglandins 
b.oxytocin 
a. Prostaglandins 
b.estrogens 
c.relaxins 
d.DHEA 
e.Antiprogestins 
  mechanical 1.bougies 
2.hygroscopic 
tents 
3.catheters and 
balloons 
 
2. Moderately 
favourable 
cervix(all 
multiparous and 
nulliparous 5-8) 
Mechanical 1.aminotomy  
  Medical 1.oxytocin 
2.prostaglandins
 
3. Favourable 
cervix(>8) 
Mechanical 1.sweep and 
stretch 
2.amniotomy 
 
 
70 
CLINICAL RECOMMENDATIONS FOR INDUCTION OF 
LABOUR(ACOG): 
Specific clinical recommendations and conclusions, all based on good 
and consistent scientific evidence(level A),are as follows: 
1. For cervical ripening and labour induction, prostaglandin E analogues 
are effective. 
2. When labour induction is indicated, low dose or high dose oxytocin 
regimens are appropriate. 
3. Regardless of Bishop score, the most efficient method of labour 
induction before 28 weeks of gestation appears to be vaginal 
misoprostol.However, infusion of high dose oxytocin is also an 
acceptable option. 
4. For cervical ripening and induction of labour, an appropriate initial 
dose of misoprostol is approximately 25microgms,with frequency of 
administration not to exceed 1 dose every 3-6 hours 
5. In women with previous caesarean delivery or major uterine surgery, 
the use of misoprostol should be avoided in the third trimester 
because it has been linked to a greater risk for uterine rupture.  
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 Prostaglandin gel has been used for cervical ripening for a very long 
period of time.  The PGE2 gel as a mode of induction is time tested and 
research proven. The dose of 0.5mg has been the standard. Over a period 
of time the advantages and disadvantages of PGE2 gel by improving the 
cervical scoring range from 3 to 7 points[80,81]. There are also  studies that 
has shown that PGE2 gel has shorter induction delivery interval(23) and 
the need for acceleration and augmentation is also less(28). PGE2 gel 
major disadvantage is that it has high incidence of hyperstimulation(34). 
PGE2 gel has been approved by FDA in the induction of labour. 
 
            Misoprostol is a synthetic analogue which is not approved by 
FDA for induction and cervical ripening but American college of 
obstetrics and gynecology advocates misoprostol and it is on WHO 
essential drug list for labour induction(26). Initially approved for 
prevention and treatment of gastric ulcer associated with use of non 
steroidal anti inflammatory drugs. Exogenously administered 
prostaglandins are relatively newer prostaglandins used for induction of 
labour. Initially PGE2 gel was used intracervically due to high cost and 
cold storage problems and so now is being replaced by newer PGE1 
tablets for effective and safe induction. Misoprostol tablets acts as 
effective myometrial stimulants, is quiet stable in vivo and is rapidly 
absorbed orally and vaginally. Well controlled studies indicates its 
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efficacy via oral route(27). Misoprostol is rapidly absorbed orally(4) and, 
although not formulated for parenteral use, can also be administered 
sublingually(5), rectally(6), and vaginally. It is compared to other 
preparations of prostaglandins and does not require refrigerated transport 
or storage(28). It has the potential for providing increased patient 
satisfaction because of its noninvasive route of administration. Moreover, 
the possibility of misplacement is eliminated, These characteristics make 
it particularly suitable for use in developing countries. Because of its 
uterotonic and cervical ripening activity, wide- ranging off-label uses 
have been introduced for misoprostol(29)  
 
 In this study comprising of 211 antenatal mothers, 104 mothers 
received oral misoprostol 25 microgm and 107 mothers received 
prostaglandin E2 gel 0.5mg as a mode of induction and their efficacy in 
cervical ripening and induction of labour was compared. The secondary 
outcomes like change in bishop score ,time interval from induction to 
onset of adequate uterine contraction, the need for augmentation of 
labour, mode of delivery, side effects, patient satisfaction and cost of 
induction and neonatal outcome were also compared. 
 
 Misoprostol has been the subject of numerous recent articles 
describing its use as a cervical ripening agent. Doses of 25 to 50 
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microgram administered orally have been shown to be effective in 
inducing labour and cervical ripening(50). Tabor et al have shown that it is 
an effective agent for cervical ripening and labour induction in patients 
with viable pregnancies. In this study the most common indication was 
term patients who did not enter into spontaneous labour followed by post 
dated post dated pregnancy. Ngai et al did a double blind randomised trial 
with 200 microgm of oral misoprostol who showed that even though 
bishop score improved very significantly with such high dose, the 
incidence of uterine rupture was also present (33). Cheng SY et al showed 
that inorder to avoid hyperstimulation, current suggestion are in favour of 
oral misoprostol given in small frequent dose(36). The same suggestion 
was given by shazia syed et al(45) and kundodyiwa TW et al(46). In a trial 
conducted in Bahawal Victoria hospital where multiparous women were 
induced with 50 microgm oral misoprostol and the incidence of 
hyperstimulation was around 9%(57). In a Cochrane review it seems that 
though high dose(100 microgm) are more effective , with more successful 
vaginal deliveries within 24 hrs, however stronger uterine contractions 
and shorter labour duration have to be carefully balanced against more 
uterine hyperstimulation, adverse neonatal outcomes and possibility of 
uterine rupture. ACOG committe also emphasizes that 25 microgm 
should be considered as an initial dose in inducing labour in third 
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trimester to minimise the risk of hyperstimulation and uterine rupture and 
it should not be administered more frequently than every 3-6 hours(59). 
The dose in this study used was 25 microgm used every 6 hours (max 
dose:75 microgm) inorder to avoid the complication of high dose. There 
was no hyperstimulation and uterine rupture in this study. 
 
 In both the groups the preinduction score taken was <5 and it was 
statistically similar. There was significant change in bishop score in both 
the groups but in oral misoprostol the cervix once it became very 
favourable it progressed very quickly with a significant difference of 
p<0.001. If the preinduction score was very less the number of doses 
required for induction was more in both the groups. In comparing the post 
bishop score among the two groups, improvement in bishop score 
especially with prescore ranging from 0-3 is better with PGE2 gel when 
compared to oral misoprostol(post score 0-3, 13.4% in oral misoprostol 
Vs 4.8% in PGE2 gel). This implies that PGE2 gel would be a better 
mode of induction with a very unfavourable cervix. 
 
 Many studies have show that oral misoprostol when compared to 
dinoprostone gel is associated with low incidence of caesarean section. In 
Nigam’s(200 microgm single dose) , Dallen’s(50 microgm) and 
Dodd’s(25 microgm) studies this rate was 22.7%,1.8% and 
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8.3%respectively (42). In this study the incidence of cesarean section was 
31.7%  oral misoprostol Vs 34.6% in PGE2 gel but it was not statistically 
significant. Shazia syed et al, Sanchez Ramos et al showed statistically 
insignificant incidence in both the groups. The most common indication 
for caesarean section in this study was fetal distress(42.4% in oral 
misoprostol). 
 
There were five studies comparing low dose oral misoprostol (25 
mcg) with dinoprostone gel which showed that the need for augmentation 
with oxytocin was similar in both the groups(62).In this study both the 
groups labour was augmented. The need for augmentation was more with 
PGE2 gel especially with vaginal misoprostol. In oral misoprostol group 
only 38% needed augmentation and among them 39.4% had failed 
induction and those people were again induced with PGE2 gel(51%). 
Among those who were reinduced with PGE2 gel only 1 patient delivered 
vaginally and rest underwent caesarean section. From this we assume that 
if the cervix becomes favourable with oral misoprostol they progress 
without any difficulty but if they don’t even if other methods are used 
they do not respond. 37 pateints in oral misoprostol group did not need 
acceleration and 100 pateints in PGE2 gel group needed acceleration and 
in that 60% needed both synto and artificial rupture of membrane. 64% 
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oral misoprostol group needed acceleration and in that only 37% needed 
acceleration with both synto and ARM. 
 
Abbassi’s study with low total dose of 150 microgm the induction 
delivery interval was shorter (mean 6.7+/- 4.4 hrs)(40). Dodd et al 
showed that with very low dose vaginal birth was not achieved within 24 
hours in comparison to dinoprostone 0.5mg gel(42). Sanchez ramos in his 
study  comparing oral misoprostol 25mcg with vaginal dinoprostone gel 
0.5 mg showed shorter induction delivery interval with oral misoprostol 
with mean duration being 12-24hrs. Wing et al showed that with low dose 
of 25mcg the induction delivery interval will be longer in contrast to 50 
mcg(38,61). WHO analysis(64) reviewing 10 trials also concluded that there 
is no significant difference in induction delivery interval between oral 
misoprostol and dinoprostone gel.  The mean induction delivery interval 
is more with oral misoprostol. But 20 patient in oral misoprostol group 
had relatively shorter duration in contrast to 15 patients in PGE2 gel. 
Though 8.7% in oral misoprostol had interval >48hrs in contrast to PGE2 
1.9% it was not statistically significant. In oral misoprostol group with 
duration more than 48 hours most of them delivered only by caesarean 
section. 
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Dodd’s and Khatri’s study the incidence of meconium stained 
liquor was 16.2% and 12%(43). Dodd et al showed that the incidence of 
fetal distress (8.8% 25mcg misoprostol Vs 9.3 % in dinoprostone gel) and 
incidence of hyperstimulation (0.8% 25mcg misoprostol Vs 1.6 % in 
dinoprostone gel). Snachez Ramos showed that those who received 
misoprostol were twice likely to experience hyperstimulation and 
tachysystole (56). Low dose oral misoprostol in comparison with vaginal 
misoprostol was associated with less risk of hyperstimulation 
(2%Vs13%).  In a randomised trial conducted in Adelaide university 
showed that there is no significant difference in incidence of 
hyperstimulation and fetal distress in patients induced with oral 
misoprostol and dinoprostone gel (42). Langennegger et al (67) showed that 
there is no significant difference in frequency of fetal heart rate 
abnormalitie between oral misoprostol 50 mcg Vs dinoprostone 0.5mg.In 
this study Incidence of complication is less in oral misoprostol 26.9%. 
among them only 25% had fetal distress and none had hyperstimulation. 
In PGE2 gel group 44.8% had complication and in them 43% had fetal 
distress and 4% had hyperstimulation. But overall the incidence of 
complication in both the groups are not statistically similar. 
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                     The incidence of meconium aspiration syndrome in study by 
Shazia Syed et al was 10.8% and 95% had good apgar score. In trial 
conducted with 50mcg oral misoprostol versus vaginal misoprostol the 
incidence of neonatal admission was more with oral 
misoprostol(12%Vs4%). Wing et al (38) showed that the neonatal 
admission was not significant between 25 and 50 mcg oral misoprostol. 
In this study the apgar score assessed at 1 minute and 5 minute was 
statistically insignificant. No respiratory distress, NICU admission and 
neonatal death is noted in both the groups. 
 
The other complication like fever, vomiting and gastrointestinal 
disturbance was more with oral misoprostol than with dinoprostone gel as 
seen from this study. The incidence of post natal complication like 
complete perineal tear and retained placenta was statistically 
insignificant. 
 
Women’s satisfaction with oral misoprostol was assessed formally 
in only one study(42) and more than half the women expressed a 
preference for oral induction agent. The cost of induction inferred from 
this study is that the amount needed for induction with PGE2 gel was 
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almost 10 times more than that needed for oral misoprostol. All these 
advantages makes oral misoprostol a better induction agent.  
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Conclusion 
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CONCLUSION 
 
• In our  study, 217 singleton primigravida who consented for the 
study and in whom cervical ripening and labour induction was 
indicated were studied. 104 women received misoprostol 
25microgm oral and 107 women received dinoprostone gel 0.5mg 
intracervically. 
• The overall improvement in bishop score was better with oral 
misoprostol. 
• There was a significant change in bishop score in both groups but 
in oral misoprostol, the cervix once it became favourable it 
progressed very smoothly. 
• The need for augmentation with vaginal misoprostol is less with 
oral misoprostol (27.9%) when compared to PGE2 gel (51.4%). 
• 35.6% of oral misoprostol did not need acceleration when 
compared to PGE2 gel 6.5%. 
• In those who needed acceleration with both oxytocin and ARM 
was less with oral misoprostol 35.6% when compared to PGE2 gel 
56.1%. 
• The  incidence of LSCS in oral misoprostol  31.7% when 
compared to PGE2 gel 34.6%. 
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• 20.2% had induction delivery interval less than 12 hrs when 
compared to PGE2 gel 14.0% 
• Incidence of complication is less in oral misoprostol (26.9%). 25% 
had fetal distress and none had hyperstimulation in oral 
misoprostol where as PGE2 gel 43% had fetal distress and 4% had 
hyperstimulation. 
• There were  no NICU admission and neonatal asphyxia in both the 
groups.  
• The incidence of complication was not statistically significant 
between the two groups, but the incidence of hyperstimulation was 
present only with PGE2 gel. 
• Both group ‘s satisfaction were assessed and they expressed a 
preference to oral misoprostol because of its ease of administration 
and cost effectiveness. 
• Post induction bishop score of 0-3 is more in oral misoprostol 
(13.4%) post induction score of 0-3 in PGE2 is less when 
compared. (4.8%) 
• This shows that with very unfavourable cervix PGE2 gel is a better 
method of induction when compared to oral misoprostol. 
• The induction delivery interval was > 48 hours in .8.7% in oral 
misoprostol and 1.9% in PGE2 gel delivered by cesaerean section. 
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In case of prolonged labor with failed induction, other modes of 
induction also failed to improve the bishop score. 
• The number of doses needed for augmentation is more with oral 
misoprostol because of difference in the route of administration 
and bio availability of the drugs. 
 
Hereby we conclude saying oral misoprostol is as efficacious as 
PGE2 gel in induction of labor. 
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Statistical Methods 
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STATISTICAL METHODS 
Descriptive and inferential  statistical analysis has been carried out 
in the present study. Results on continuous measurements are presented 
on Mean ± SD (Min-Max) and results on categorical measurements are 
presented in Number (%). Significance is assessed at 5 % level of 
significance. The following assumptions on data is made, Assumptions: 
1.Dependent variables should be normally distributed, 2.Samples drawn 
from the population should be random, Cases of the samples should be 
independent 
Student t test ( two tailed, independent)  has been used to find the 
significance of study parameters on continuous scale between two groups 
Inter group analysis) on metric parameters. Chi-square/ Fisher Exact test 
has been used to find the significance of study parameters on categorical 
scale between two or more  groups. 
Significant figures  
+ Suggestive significance (P value: 0.05<P<0.10) 
* Moderately significant  ( P value:0.01<P ≤ 0.05) 
** Strongly significant   (P value : P≤0.01) 
Statistical software: The Statistical software namely SAS 9.2, SPSS 
15.0, Stata 10.1, MedCalc 9.0.1 ,Systat 12.0 and R environment 
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ver.2.11.1 were used for the analysis of the data and Microsoft word and 
Excel have been used to generate graphs, tables etc.  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix 


 
 
PSG Institute of Medical Science and Research, Coimbatore 
Institutional Human Ethics Committee 
INFORMED CONSENT 
 
 
I , Dr.Meenakshi Priya MD.,(OG) postgraduate from the department of Obstetrics and 
Gynecology of PSG Institue of Medical Science & Research (PSGIMS&R), am carrying out 
a study on the topic: A comparative study of safety and efficacy of oral misoprostol (25 
microgram) with dinoprostone gel (0.5mg) for cervical ripening and induction of labour. 
under the aegis of the Department of Obstetrics and Gynecology, PSGIMSR   
The objectives of this study are: 
To compare safety and efficacy of oral misoprostol (25 microgram) with dinoprostone gel 
(0.5mg) for cervical ripening and induction of labour. 
Sample size: 217 
Respondants are term antenatal patients who are for induction of labor in PSG hospitals – 
labour ward,coimbatore 
 
Consent: The above information regarding the study, has been read by me/ read to me, and 
has been explained to me by the investigator/s. Having understood the same, I hereby give 
my consent to them to interview me. I am affixing my signature / left thumb impression to 
indicate my consent and willingness to participate in this study.  
 
Signature / Left thumb impression of the Study Volunteer / Legal Representative:  
 
 
 
Signature of the Interviewer with date:      Witness: 
PROFORMA 
NAME: 
AGE: 
SNO: 
OP NO: 
IP NO: 
ADDRESS: 
UNIT: 
SOCIO ECONOMIC STATUS: 
 
MENSTRUAL H/O: 
 
OBSTETRIC HISTORY: 
 
ANTENATAL COMPLICATION: 
 
INDICATION FOR INDUCTION: 
 
O/E: 
PR: 
BP: 
TEMP: 
PALLOR: 
ICTERUS: 
CVS: 
RS: 
P/A: 
 UTERINE HEIGHT: 
 PRESENTING PART: 
 FETAL HEART: 
 
MODE OF INDUCTION: 
DATE: 
TIME: 
P/V: 
FACTORS 0 1 2 3 
DILATATION CLOSED 1-2 3-4 >5 
EFFACEMENT 25 50 75 >80 
CONSISTENCY FIRM MED SOFT - 
POSITION POST MID ANT - 
STATION -3 -2 -1,0 +1,+2 
TOTAL  FAVOURABLE UNFAVOURABLE  
 
 
REINDUCTION SCORE         
  
 
REASSESSMENT: 
 
 
FACTORS 0 1 2 3 
DILATATION CLOSED 1-2 3-4 >5 
EFFACEMENT 25 50 75 >80 
CONSISTENCY FIRM MED SOFT - 
POSITION POST MID ANT - 
STATION -3 -2 -1,0 +1,+2 
TOTAL  FAVOURABLE UNFAVOURABLE  
 
POSTINDUCTION SCORE: 
 
NON STRESS TEST: 
 
MODE OF DELIVERY: 
 
INDICATION: 
 
INDUCTION DELIVERY INTERVAL: 
 
BABY DETAILS: 
 SEX : 
 WEIGHT: 
 APGAR: 
 NICU ADMISSION: 
 
MATERNAL COMPLICATION 
 
COST OF INDUCTION: 
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1 21 primi 39w Oligo 3/13 10/13 cytotec Synto+ARM LSCS non progression of labour 20 hrs 2 nil 8 9 450 nil 
2 23 primi 39w+6d term   3/13 10/13 nil ARM NVD nil 10hrs 2 nil 8     9     450 nil 
3 24 primi 38W+6D NR, NST   4/13  5/13
Cytote
c ARM NVD nil 29hrs 2 nil 8     9     450 nil 
4 18 primi 37W
pre 
eclampsia   3/13  7/13 nil Synto+ARM NVD nil 19hrs 2 nil 8     9     450 nil 
5 27 primi 38w+5d GDM   2/13  9/13
Cytote
c Synto+ARM NVD nil 48hrs 3
fetal 
distress 8     9     675 nil 
6 26 primi 39w+6d term   4/13  7/13 nil Synto NVD nil 48hrs 3 nil 8     9     675 nil 
7 23 primi 37W Oligo   3/13  7/13
Cytote
c Synto+ARM NVD nil 20hrs 2 nil 8     9     450 nil 
8 29 primi 38w GDM   3/13  9/13 nil Synto+ARM NVD nil 12hrs 2
hypersti
mulation 8     9     450 nil 
9 30 primi 38W+4d term   4/13 10/13 nil ARM NVD nil 10hrs 1 nil 8     9     225 PPH 
10 21 primi 37w+4d TERM   1/13  3/13 cytotec Synto LSCS fetal distress 34hrs 3
fetal 
distress 7     8     675 NIL 
11 21 primi 39w oligo   2/13  5/13
Cytote
c Synto+ARM LSCS
non progression 
of labour 54hrs 3 nil 8     9     675 nil 
12 24 primi 38w+2d Oligo   3/13  4/13
Cytote
c Synto+ARM LSCS failed induction 34 hrs 3 fever 7     8     675 nil 
13 23 primi 40w+2d postdated   3/13  7/13
Cytote
c Synto LSCS
non progression 
of labour 48hrs 2 nil 7     8     450 nil 
14 24 primi 40w+2d postdated   2/13  3/13 nil ARM LSCS fetal distress 8h 1
fetal 
distress 5 6     225 nil 
15 25 primi 39w Oligo   2/13  5/13
Cytote
c Synto NVD nil 48hrs 3 nil 8     9     675 
retained 
placenta 
16 24 primi 39w+2d Oligo   1/13  3/13 nil Synto LSCS fetal distress 13hrs 2
fetal 
distress 7 8     450 nil 
17 27 primi 40w+2d post dated   2/13  7/13 nil Synto NVD nil 24hrs 2 nil 8     9     450 nil 
18 29 primi 37w+5d IuGR   4/13  6/13 cytotec Synto+ARM NVD nil 28hrs 2
fetal 
distress 8     9     450 nil 
19 23 primi 40w GDM   2/13  7/13 nil Synto+ARM NVD nil 14 hrs 1 nil 8     9     225 nil 
20 24 primi 39w+3d GDM   2/13  9/13 nil Synto NVD nil 17 hrs 2
fetal 
distress 8     9     450 nil 
21 27 primi 40w+1d postdated   3/13  7/13 nil Synto NVD nil 26hrs 3 nil 8     9     675 nil 
22 24 primi 39w IUGR   4/13  5/13 cytotec Synto+ARM NVD nil 48 hrs 3 nil 8     9     675 nil 
23 24 primi 38w+2d
pre 
eclampsia   1/13  3/13 cytotec ARM LSCS failed induction 37 hrs 3
fetal 
distress 7     8     675 nil 
24 30 primi 38w+4d IUGR   3/13 10/13 nil ARM NVD nil 12 hrs 1 nil 8     9     225 nil 
25 25 primi 40w+1d postdated   3/13  5/13 cytotec Synto+ARM NVD nil 38 hrs 3 nil 8     9     675 nil 
26 23 primi 40w+1d post dated 0/13  8/13 nil ARM NVD nil 10hrs 1 nil 8     9     225 nil 
27 28 primi 40w+1d post dated   4/13  8/13 nil ARM NVD nil 8 hrs 9 min 1 nil 8     9     225 PPH 
28 23 primi 38w+5d
non 
reassuring, 
NST   2/13  6/13 nil Synto+ARM NVD nil 16hrs 1
fetal 
distress 8     9     225 nil 
29 25 primi 38w Oligo   1/13  5/13 cytotec Synto+ARM NVD nil
25 hrs 53 
min 2 nil 8     9     450 nil 
30 27 primi 39w+6d term   1/13  8/13 nil Synto NVD nil 20 hrs 2 nil 8     9     450 nil 
31 21 primi 40w+2d post dated   2/13  7/13 cytotec Synto+ARM LSCS fetal distress 29 hrs 3
fetal 
distress 7     8     675 nil 
32 18 primi 40w+2d post dated   1/13  7/13 nil Synto+ARM NVD nil
22 hrs 10 
min 3 nil 8     9     675 nil 
33 20 primi 40w+1d post dated   1/13  6/13 nil Synto LSCS fetal distress 29 hrs 3
fetal 
distress 8     9     675 nil 
34 28 primi 37 w Oligo   1/13 10/13 nil Synto NVD nil 22hrs 2 nil 7     8     450 nil 
35 23 primi 40w+1d post dated   2/13  7/13 nil Synto+ARM LSCS fetal distress 
22 hrs 33 
min 2
fetal 
distress 8     9     450 nil 
36 19 primi 38w Oligo   4/13  8/13 nil ARM NVD nil 28hrs 3 nil 4     6     675 nil 
37 21 primi 40w+1d post dated   3/13  5/13 cytotec Synto+ARM NVD nil 30hrs 3 nil 8     9     675 nil 
38 21 primi 38w+5d Oligo   4/13  8/13 nil Synto+ARM NVD nil
13 hrs 12 
min 2 nil 4     6     450 nil 
39 22 primi 40w+1d post dated   1/13  2/13 nil Synto+ARM LSCS failed induction 
23 hrs 42 
min 3
fetal 
distress 8     9     675 nil 
40 28 primi 39w+6d term   3/13  6/13 cytotec Synto+ARM NVD nil
14hrs 24 
min 1 nil 8     9     225 nil 
41 24 primi 39w+5d term   3/13  6/13 nil Synto LSCS fetal distress 
13 hrs 26 
min 2
fetal 
distress 8     9     450 nil 
42 23 primi 37w+4d Oligo 0/13  5/13 nil Synto+ARM NVD nil
13 hrs 52 
min 3
fetal 
distress 8     9     675 nil 
43 25 primi 39w+1d term   1/13  6/13 nil ARM LSCS fetal distress 
23hrs 45 
min 3
fetal 
distress 7     8     675 nil 
44 23 primi 40w+1d postdated   4/13  7/13 cytotec Synto+ARM LSCS fetal distress 
20 hrs 45 
min 2
fetal 
distress 5     5     450 nil 
45 22 primi 37w+3d IUGR   3/13  6/13 nil Synto+ARM NVD nil
19 hrs 22 
min 2 nil 8     9     450 nil 
46 25 primi 40w term   2/13  5/13 nil nil LSCS fetal distress 
20 hrs 49 
min 3
fetal 
distress 8     9     675 nil 
47 23 primi 39w term   4/13  6/13 cytotec Synto+ARM NVD nil
42 hrs 45 
min 3
fetal 
distress 6     7     675 nil 
48 22 primi 40w term   4/13  5/13 nil Synto+ARM NVD nil 17 hrs 1 nil 7     8     225 nil 
49 23 primi 40w term   3/13  9/13 nil Synto+ARM NVD nil
12 hrs 17 
min 1 nil 8     9     225 nil 
50 24 primi 40w term   4/13  5/13 cytotec Synto+ARM NVD nil 29 hrs 2 nil 7     8     450 nil 
51 21 primi 40w term   3/13  6/13 cytotec Synto+ARM NVD nil
27 hrs 8 
min 2 nil 7     8     450 nil 
52 23 primi 40w+1d post dated   4/13 10/13 nil ARM NVD nil
5 hrs 33 
min 1 nil 8     9     225 nil 
53 22 primi 38w GDM   3/13  5/13 nil nil LSCS fetal distress 14hrs 2
hypersti
mulation 5     6     450 nil 
54 24 primi 38w+2d term   3/13  4/13 cytotec Synto+ARM LSCS fetal distress 26hrs 3
fetal 
distress 6     7     675 nil 
55 26 primi 40w+2d post dated   4/13  5/13 cytotec Synto+ARM NVD nil
29 hrs 15 
min 3
fetal 
distress 4     8     675 nil 
56 29 primi 40w+2d post  dated   3/13  6/13 cytotec Synto NVD nil
28 hrs 49 
min 3 nil 8     9     675 nil 
57 24 primi 40w term   3/13  6/13 cytotec Synto+ARM NVD nil
15 hrs 
30min 1 nil 8     9     225 nil 
58 23 primi 38w oligo   3/13  6/13 cytotec Synto+ARM LSCS fetal distress 37 hrs 3
fetal 
distress 8     9     675 nil 
59 24 primi 40w term   3/13  9/13 nil ARM NVD nil
9 hrs 48 
min 1 nil 8     9     225 nil 
60 23 primi 40w term   2/13 10/13 nil Synto NVD nil 18 hrs 2 nil 8     9     450 nil 
61 25 primi 40w term   1/13  6/13 cytotec Synto+ARM NVD nil 40 hrs 2
fetal 
distress 6     7     450 nil 
62 23 primi 38w term   4/13 10/13 nil ARM NVD nil 16 hrs 2 nil 8     9     225 nil 
63 25 primi 38w Oligo   2/13  4/13 nil Synto+ARM LSCS fetal distress 17hrs 2
fetal 
distress 8     8     450 nil 
64 23 primi 40w term   4/13  6/13 cytotec Synto+ARM LSCS fetal distress 
27 hrs 49 
min 3
fetal 
distress 5     6     675 nil 
65 21 primi 38w
severe  PE, 
IUGR   4/13  6/13 cytotec Synto+ARM NVD nil
25 hrs 37 
min 2 nil 8     9     450 nil 
66 22 primi 40w term   3/13  3/13 cytotec nil LSCS failed induction 77 hrs 3 nil 8     9     675 nil 
67 26 primi 40w+1d postdated   4/13  6/13 cytotec Synto+ARM NVD nil 37 hrs 2 nil 8     9     450 nil 
68 25 primi 40w term   3/13  5/13 cytotec Synto+ARM NVD nil 37 hrs 2 nil 8     9     450 nil 
69 25 primi 39w term   2/13 10/13 nil Synto NVD nil 12hrs 1
fetal 
distress 8     9     225 nil 
70 26 primi 40w term   4/13  5/13 cytotec ARM LSCS fetal distress 
24 hrs 35 
min 1
fetal 
distress 8     9     225 nil 
71 25 primi 40w+1d post dated   3/13  5/13 cytotec Synto+ARM NVD nil
20 hrs 39 
min 2 nil 8     9     450 nil 
72 24 primi 40w term   2/13  6/13 cytotec Synto+ARM NVD nil 16 hrs 1
fetal 
distress 8     9     225 nil 
73 21 primi 40w term   3/13  9/13 nil ARM NVD nil 6  1/2 hrs 1 nil 8     9     225 nil 
74 22 primi 39w+2d Oligo   3/13  7/13 cytotec Synto+ARM NVD nil 29 hrs 1
fetal 
distress 8     9     225 nil 
75 21 primi 40w term   2/13  6/13 cytotec Synto+ARM NVD nil
12 hrs 18 
min 1
fetal 
distress 7     9     225 nil 
76 21 primi 39w Oligo   4/13  5/13 cytotec Synto NVD nil
26 hrs 13 
min 1 nil 8     9     225 nil 
77 24 primi 39w term   2/13  9/13 nil Synto+ARM NVD nil
15 hrs 22 
min 2
fetal 
distress 8     9     450 nil 
78 26 primi 40w term   2/13  7/13 nil Synto LSCS fetal distress 17 hrs 1
fetal 
distress 7     8     225 nil 
79 24 primi 40w term   2/13  4/13 cytotec Synto+ARM LSCS
non progression 
of labour 21 hrs 1
fetal 
distress 7     8     225 nil 
80 24 primi 40w+1d post dated   1/13  2/13 cytotec Synto+ARM NVD 28 hrs 2 nil 8     9     450 nil 
81 19 primi 39w term   4/13  4/13 nil nil LSCS fetal distress 8 hrs 1
hypersti
mulation 6     8     225 nil 
82 23 primi 40w+1d postdated   2/13  4/13 cytotec Synto+ARM NVD nil 14 hrs 1 nil 8     9     225 nil 
83 23 primi 38w+4d
pre 
eclampsia   2/13  4/13 cytotec Synto+ARM NVD nil 26  hrs 2 nil 7     8     450 PPH 
84 25 primi 40w term   4/13  6/13 nil Synto NVD nil 20hrs 2 nil 8     9     450 nil 
85 24 primi 40w+2d postdatism   2/13  3/13 cytotec Synto+ARM LSCS nil 34hrs 3
fetal 
distress 8     9     675 nil 
86 23 primi 39w+2d
precious 
pres   4/13  5/13 cytotec Synto+ARM LSCS nil 33 hrs 2 nil 8     9     450 nil 
87 23 primi 40w+1d postdated   4/13  7/13 nil Synto NVD nil 12 hrs 1
fetal 
distress 7     8     225 nil 
88 24 primi 40 w term   2/13  4/13 cytotec Synto+ARM NVD nil 20 hrs 1 nil 8     9     225 nil 
89 24 primi 38 w
GDM  on 
insulin   4/13  5/13 cytotec Synto+ARM NVD nil 32 hrs 2 nil 8     9     225 nil 
90 26 primi  40 w term   2/13  4/13 cytotec Synto+ARM NVD nil 18 hrs 1
fetal 
distress 7     8     225 nil 
91 26 primi 40w term   4/13  8/13 nil Synto NVD nil 12 hrs 1
fetal 
distress 8     9     225 nil 
92 25 primi 40w+1d postdated   2/13  3/13 cytotec Synto+ARM LSCS
non progression 
of labour 30hrs 3
fetal 
distress 8     9     675 nil 
93 23 primi 40w+2d postdated   3/13  5/13
Cytote
c ARM LSCS
non progression 
of labour 37 hrs 2 nil 8     9     450 nil 
94 29 primi 38 w
GDM on 
insulin   3/13  8/13 nil Synto NVD nil 10hrs 1 nil 8     9     225 nil 
95 29 primi 40w+2d postdated   4/13  4/13 cytotec Synto+ARM LSCS fetal distress 24 hrs 2
fetal 
distress 6     9     450 nil 
96 24 primi 40w term   2/13  5/13 nil ARM LSCS fetal distress 16hrs 2
fetal 
distress 5     7     450 nil 
97 24 primi 39w
GDM on 
diet   3/13  4/13 cytotec Synto+ARM NVD nil
36 hrs 37 
min 2 nil 8     9     450 nil 
98 19 primi 40w term   3/13  7/13 nil Synto NVD nil
12 hrs 28 
min 1 nil 7     8     225 nil 
99 23 primi 40w+6d postdated   3/13  4/13 nil nil LSCS fetal distress 13 hrs 2
fetal 
distress 8     9     450 nil 
100 23 primi 40w+1d postdated   2/13  5/13 nil Synto+ARM NVD nil 13hrs 1 nil 8     9     225 nil 
101 25 primi 40w term   2/13  3/13 cytotec nil LSCS failed induction 36hrs 3 nil 8     9     675 nil 
102 26 primi 39w term   4/13  4/13 cytotec Synto+ARM NVD nil 28 hrs 2 nil 8     9     450 nil 
103 26 primi 38w Oligo   3/13  9/13 nil ARM NVD nil 19 hrs 2
hypersti
mulation 8     9     450 nil 
104 26 primi 39w+6d term   2/13  4/13 cytotec Synto+ARM NVD nil
32hr 30 
min 2 nil 8     9     450 nil 
105 24 primi 40w term   2/13  3/13 nil nil LSCS fetal distress 14hrs 1
fetal 
distress 8     9     225 nil 
106 23 primi 40w term 0/13  5/13 nil Synto+ARM LSCS fetal distress 21 hrs 3
fetal 
distress 7     8     675 nil 
107 28 primi 40w+1d term   2/13  3/13 cytotec Synto+ARM LSCS
non progression 
of labour 23hrs 3
fetal 
distress 8     9     675 nil 
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1 20 primi 38wks Chronic SHT   4/13  7/13 cytotec Synto NVD 49 hrs 3 nil 8 9 PPH 12 
2 25 primi 39w+2d Term   1/13 10/13 nil nil LSCS failed 
induction 
29hrs 3 fetal 
distress
8 9 nil 12 
3 18 primi 41w postdated   4/13 11/13 nil nil NVD 22hrs 2 fetal 
distress
8 9 nil 8 
4 28 primi 40w Term   2/13  7/13 nil nil NVD 12 hrs 1 nil 8 9 nil 4 
5 29 Primi 37w Non reactive 
NST 
  3/13  9/13 nil nil LSCS fetal 
distress 
21hrs 23 
min
3 fetal 
distress
7 8 nil 12 
6 34 Primi 39w+3d term   3/13  9/13 cytotec Synto NVD nil 29hrs 3 nil 8 9 nil 12 
7 23 primi 39w+6D term   1/13  9/13 cytotec Synto NVD nil 32hrs 3 nil 8 9 nil 12 
8 27 Primi 39w oligo   3/13 10/13 nil nil NVD nil 11 hrs 1 nil 8 9 nil 4 
9 25 Primi 40w term   1/13  9/13 nil ARM NVD nil 12 hrs 1 nil 8 9 nil 4 
10 24 primi 40w term   1/13  7/13 nil Synto NVD nil 24hrs 3 fetal 
distress
8 9 nil 12 
11 23 primi 37w+4d term   1/13  7/13 cytotec nil LSCS fetal 
distress 
33h 3 fetal 
distress
8 9 nil 12 
12 26 primi 40w term   3/13  8/13 cytotec nil NVD nil 29hrs 3 nil 8 9 nil 12 
13 23 primi 38w+2d term   4/13  6/13 nil nil NVD nil 14 hrs 1 nil 8 9 nil 4 
14 28 Primi 37w+3D term   1/13  9/13 nil Synto NVD nil 18hrs 2 nil 8 9 nil 8 
15 24 primi 38w+4d term   3/13  9/13 nil nil NVD nil 14hrs 2 nil 7 9 nil 8 
16 23 primi 40w term   3/13  7/13 nil Synto NVD nil 23hrs 3 nil 7 8 nil 12 
17 24 primi 37w+2D Oligo   4/13 10/13 nil nil NVD nil 5hrs 1 nil 8 9 nil 4 
18 23 Primi 39w IUGR   4/13 10/13 nil ARM NVD nil 12hrs 1 nil 8 9 nil 4 
19 27 Primi 40w term   3/13 10/13 nil nil NVD nil 6hrs 1 nil 8 9 nil 4 
20 26 primi 40w term   4/13 10/13 nil Synto+ARM NVD nil 24 hrs 2 nil 8 9 nil 8 
21 23 primi 38w GDM   3/13  8/13 cytotec nil LSCS non 
progressio
n of labour
57hrs 3 nil 8 9 nil 12 
22 23 Primi 40w term   2/13  9/13 nil nil LSCS fetal 
distress 
15hrs 2 fetal 
distress
4 8 nil 8 
23 24 primi 40w term   3/13  6/13 cytotec nil NVD nil 24hrs 2 nil 8 9 nil 8 
24 23 primi 40w+1d postdated   4/13 10/13 nil nil NVD nil 6hrs 1 nil 8 9 nil 4 
25 21 primi 40+2 postdated   1/13  9/13 Cytotec nil NVD nil 36hrs 3 nil 8 9 nil 12 
26 21 primi 39w Oligo   4/13  9/13 nil nil NVD nil 16hrs 2 nil 8 9 nil 8 
27 20 primi 39w term   3/13  4/13 cytotec nil LSCS non 
progressio
n of labour
48hrs 3 fetal 
distress 
7 8 nil 12 
28 24 primi 40w term   3/13  8/13 cytotec nil LSCS failed 
induction 
54 hrs 3 nil 8 9 nil 12 
29 24 primi 40w+2 post dated   3/13  3/13 cytotec nil LSCS failed 
induction 
53 hrs 3 nil 8 8 nil 12 
30 23 primi 40w+2 post dated   3/13  8/13 nil ARM NVD nil 16hrs 2 nil 8 9 nil 8 
31 27 primi 38w Oligo   2/13  6/13 nil nil NVD nil 22hrs 3 nil 8 9 nil 12 
32 26 primi 39w Oligo   2/13  2/13 nil nil LSCS fetal 
distress 
13h 2 fetal 
distress
7 9 nil 8 
33 34 primi 40w+2d postdated 0/13  1/13 cytotec Synto+ARM NVD nil 31hrs 3 fetal 
distress
7 8 nil 12 
34 28 primi 39w+5d term   2/13  3/13 PGE2 gel nil LSCS failed 
induction 
46h 3 nil 8 9 nil 12 
35 24 primi 39w+6d term   1/13  1/13 nil Synto NVD nil 30hrs 3 nil 7 8 nil 12 
36 23 primi 37w+6d Oligo  0/13  9/13 pgE2 gel nil LSCS failed 
induction 
40 3 nil 8 9 nil 12 
37 26 primi 40w+1d post dated 0/13 10/13 nil nil NVD nil 22hrs 3 nil 8 9 nil 12 
38 26 primi 39w+4d term   4/13 10/13 nil nil NVD nil 13hrs 2 nil 8 9 nil 8 
39 26 primi 40w+1d postdated   3/13  7/13 nil Synto NVD nil 21hrs 23 
min
2 nil 8 9 nil 8 
40 23 primi 37w+6d GDM   2/13  7/13 nil Synto NVD nil 18hrs 3 nil 7 8 PPH 12 
41 23 primi 40w+1d postdated   4/13  9/13 nil ARM NVD nil 23hrs 3 nil 8 9 perine
al  tear 
12 
42 23 primi 38w+2d Oligo   2/13  6/13 nil Synto+ARM NVD nil 12hrs 1 nil 8 9 nil 4 
43 26 primi 40w+1d postdated   2/13  9/13 cytotec nil LSCS non 
progressio
n of labour
24hr30m
in 
3 nil 8 9 nil 12 
44 25 primi 39w+3d term   1/13  8/13 nil Synto+ARM NVD nil 22hr15m
in
3 nil 7 8 nil 12 
45 25 primi 40w+1d postdated   3/13  7/13 nil Synto+ARM NVD nil 24hrs 2 nil 8 9 nil 8 
46 26 primi 40w+1d postdated   2/13  8/13 cytotec Synto+ARM NVD nil 28hrs 3 nil 8 9 perine
al  tear 
12 
47 24 primi 40w+2d post dated   4/13  8/13 nil Synto+ARM NVD nil 18 hrs 9 
min
2 fetal 
distress
7 8 nil 8 
48 24 primi 40w term   4/13  8/13 cytotec Synto+ARM LSCS fetal 
distress 
29 hrs 
30 min
3 fetal 
distress
8 9 nil 12 
49 27 primi 38w+4d IUGR   4/13  8/13 cytotec Synto+ARM NVD nil 26 hrs 
43 min
2 nil 7 8 nil 8 
50 25 primi 39w+4d term   3/13  6/13 nil ARM NVD nil 5 hrs 28 
min
1 nil 8 9 nil 4 
51 23 primi 38w+6d term   1/13 11/13 PGE2 gel nil LSCS failed 
induction 
48h 3 fetal 
distress
7 9 nil 12 
52 24 primi 38w+3d term   4/13  8/13 cytotec Synto+ARM NVD nil 25 hrs 
14 min
3 nil 8 9 nil 12 
53 23 primi 40w term   3/13  7/13 PGE2 gel nil LSCS failed 
induction 
55 hrs 
52 min
3 nil 8 9 nil 12 
54 23 primi 38w+ 1d term   4/13 10/13 nil nil NVD nil 11 hrs 
21 min
2 fetal 
distress
6 7 nil 8 
55 26 primi 38w+1d term   4/13  9/13 nil nil NVD nil 21 hrs 
52 min
3 nil 8 9 nil 12 
56 26 primi 39w+1d GDM   3/13 11/13 PGE2 
gel
nil LSCS fetal 
distress 
48 hrs 3 fetal 
distress
3 7 nil 12 
57 24 primi 38w+3d term   2/13  6/13 cytotec Synto+ARM NVD nil 47 hrs 3 nil 8 9 nil 12 
58 25 primi 40w+1d postdated   4/13  9/13 nil Synto+ARM NVD nil 21 1/2 
hrs
3 fever 8 9 nil 12 
59 26 primi 38w+3d IUGR   4/13 10/13 nil ARM NVD nil 8 hrs 27 
min
1 nil 8 9 nil 4 
60 24 primi 38w+5d term   1/13  7/13 nil Synto+ARM LSCS fetal 
distress 
26 hrs 
51 min
2 nil 7 8 nil 8 
61 26 primi 39w+3d IUGR   2/13  6/13 nil ARM LSCS fetal 
distress 
16hrs 2 fetal 
distress
7 8 nil 8 
62 23 primi 40w+1d postdated   1/13  5/13 PGE2 nil LSCS failed 
induction 
32h 3 fetal 
distress
7 8 nil 12 
63 24 primi 38w   4/13 11/13 nil Synto+ARM NVD nil 7 hrs 1 nil 3 5 nil 4 
64 27 primi 39w+6d Oligo   3/13 10/13 nil nil NVD nil 9  1/2 
hrs
2 nil 8 9 nil 8 
65 24 primi 38w term   3/13  7/13 cytotec Synto+ARM NVD nil 37hrs 
24min
3 fever 6 7 nil 12 
66 24 primi 38w term   2/13  8/13 nil Synto+ARM NVD nil 24 hrs 
12min
3 fetal 
distress
6 7 nil 12 
67 24 primi 37w IUGR   2/13  8/13 PGE2 nil LSCS failed 
induction 
38h 3 nil 8 9 nil 12 
68 23 primi 38w term   3/13  6/13 cytotec Synto+ARM NVD nil 22 hrs 
20 min
2 nil 8 9 nil 8 
69 24 primi 40w+3d postdated   2/13 10/13 nil Synto NVD nil 22 hrs 3 nil 8 9 nil 12 
70 26 primi 40w term   2/13  8/13 PGE2 nil LSCS failed 
induction 
32h 3 nil 8 9 nil 12 
71 25 primi 40w+1d post dated   3/13  6/13 cytotec Synto+ARM LSCS fetal 
distress 
37 hrs 3 fetal 
distress
7 9 nil 12 
72 25 primi 38w Oligo   3/13  8/13 nil ARM NVD nil 11 hrs 1 nil 8 9 nil 4 
73 27 primi 40w term   3/13  9/13 nil ARM NVD nil 12 hrs 
18 min
1 nil 8 9 nil 4 
74 26 primi 40w+3d term   2/13 10/13 nil ARM NVD nil 22 hrs 3 nil 8 9 nil 12 
75 26 primi 40w term   1/13  7/13 cytotec Synto+ARM LSCS non 
progressio
n of labour
33 hrs 2 nil 8 9 nil 8 
76 25 primi 40w term   2/13  5/13 nil nil LSCS fetal 
distress 
10 hrs 1 fetal 
distress
8 9 nil 4 
77 23 primi 40w term   4/13  6/13 nil Synto+ARM NVD nil 15 hrs 
59 min
2 nil 8 9 nil 8 
78 23 primi 40w+1d term   2/13  8/13 cytotec Synto+ARM NVD nil 24hrs 2 fetal 
distress
8 9 nil 8 
79 25 primi 40w term   2/13  7/13 nil Synto+ARM LSCS fetal 
distress 
26hrs 3 fetal 
distress
5 8 nil 12 
80 24 primi 40w term   2/13 10/13 PGE2 Synto NVD nil 53 hrs 3 nil 8 9 nil 12 
81 24 primi 39w term   3/13  9/13 PGE2 Synto+ARM LSCS failed 
induction 
68 hrs 3 nil 8 9 nil 12 
82 25 primi 40w term   2/13  5/13 nil ARM LSCS non 
progressio
n of labour
22 hrs 
46 min 
2 fetal 
distress 
7 8 nil 8 
83 24 primi 40w+1d postdated   2/13  8/13 PGE2 Synto+ARM LSCS failed 
induction 
54 hrs 3 nil 4 7 nil 12 
84 25 primi 38w term   2/13  9/13 cytotec Synto+ARM NVD nil 42hrs 3 nil 8 9 nil 12 
85 26 primi 40w term   3/13  9/13 nil Synto+ARM LSCS fetal 
distress 
22hrs 3 fetal 
distress
8 8 nil 12 
86 26 primi 40w term   4/13  5/13 nil Synto+ARM LSCS fetal 
distress 
20 hrs 2 nil 8 9 nil 8 
87 23 primi 38w+3d Non 
reassuring 
NST 
  2/13  7/13 cytotec Synto+ARM NVD nil 54hrs 3 nil 7 8 nil 12 
88 23 primi 38w term   2/13  6/13 cytotec Synto+ARM LSCS fetal 
distress 
48 hrs 3 nil 3 3 nil 12 
89 25 primi 40w term   3/13  4/13 cytotec Synto LSCS non 
progressio
n of labour
32 hrs 3 nil 8 9 nil 12 
90 24 primi 37w+6d term   2/13  6/13 nil Synto+ARM NVD nil 20 hrs 2 fetal 
distress
8 8 nil 8 
91 25 primi 39w term   4/13  8/13 nil ARM NVD nil 9 hrs 1 nil 8 9 nil 4 
92 24 primi 39w term 0/13  6/13 nil Synto+ARM NVD nil 26h 3 nil 8 8 nil 12 
93 25 primi 38w IUGR   4/13 10/13 nil Synto NVD nil 12 hrs 
25 min
1 nil 8 9 nil 4 
94 26 primi 40w+2d postdated   2/13  7/13 nil Synto+ARM NVD nil 18 hrs 
38 min
2 nil 8 9 nil 8 
95 25 primi 41w+3d postdated   4/13 10/13 nil Synto+ARM NVD nil 12 hrs 1 nil 8 9 nil 4 
96 27 primi 38w term   4/13  8/13 nil Synto NVD nil 8 hrs 1 nil 8 9 nil 4 
97 26 primi 39w Oligo   3/13  6/13 nil ARM NVD nil 18 hrs 2 fetal 
distress
6 7 nil 8 
98 25 primi 40 term   4/13  6/13 nil Synto+ARM NVD nil 30 hrs 2 nil 8 9 nil 8 
99 23 primi 39w term   2/13  6/13 cytotec ARM NVD nil 22hrs 2 nil 8 9 nil 8 
100 24 primi 39w+2d term   2/13  6/13 nil Synto+ARM NVD nil 12 hrs 2 nil 8 9 nil 8 
101 23 primi 40w+2D post dated   2/13  6/13 cytotec ARM LSCS
failed 
induction 32 hrs 3 fever 8 9 nil 12 
102 21 primi 40w term   2/13  7/13 nil Synto+ARM NVD nil 12 hrs 1 nil 8 9 nil 4 
103 27 primi 39w term   2/13  7/13 nil Synto NVD nil 14 hrs 2 nil 8 9 nil 8 
104 23 primi 40W term   3/13  6/13 nil Synto+ARM NVD nil 18hrs 2 nil 8 9 nil 8 
 
